Therafirst Medical Centers has participated in the following Clinical Protocols:
Adria Labs
Protocol #: 087023--Rifabutin Therapy for the Prevention of Mycobacterium-avium
Complex (MAC) Bacteremia in AIDS Patients with CD4+ Counts < 200: A Double-
Blind, Placebo-Controlled Trial
Protocol # 087027----Rifabutin Therapy for the Prevention of Mycobacterium-avium
Complex (MAC) Bacteremia in AIDS Patients with CD4+ Counts < 200: A Double-
Blind, Placebo-Controlled Trial
Protocol # 087065-- A Double Blind, Random Clinical Trial of a Rifabutin regimen in
Treatment of MAC Bacteremia in Patients with AIDS
Protocol # 087085--Rifabutin Therapy for the Prevention of Mycobacterium-avium
Complex (MAC) Bacteremia in HIV Positive Patients with CD4 Counts < 200:
Treatment IND Study
Protocol # 087250--A Three-Arm Comparative Trial for the Treatment of MAC
Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (900
mg) of Rifabutin (600 mg) or Placebo
Protocol # 112010--Study of the Activity of THF-gamma 2 on HIV Load in HIV
Positive Individuals with CD4+ Cell Counts in the Range of 200 - 500/uL
Abbott Laboratories
Protocol #: M91-561--A Prospective, Randomized, Double-Blind, Multicenter, Placebo-
Controlled Study of the Safety and Efficacy of Clatithromycin for the Prevention of
Disseminated Mycobacterium-avium Complex (MAC) Infection in HIV-Infected Patients
with CD4+ Counts < 100 Cells/mm3
Protocol # M91-561X--An Open-Label Extension of the Multicenter Study (M91-561) of
the Safety and Efficacy of Clarithromycin for the Prevention of Disseminated
Mycobacterium-Avium Complex (MAC) Infection in HIV-Infected Patients with CD4+
Counts < 100 cells/mm3
Abbott Laboratories
Protocol # M92-806--An Open-Label, Multicenter Study of the Safety and Efficacy of
Clarithromycin Plus Clofazimine With or Without Ethambutol in the Treatment of
Disseminated Mycobacterium-avium Complex (MAC) Infection in HIV-Infected Patients
with CD4+ Counts < 100 Cells/mm3
Protocol # M93-134--Evaluation of Antiviral Activity, Pharmacokinetics, and Safety of
Orally-Administered ABT-538 in HIV-Infected Patients
Protocol # M93-134X--A Long-Term Safety and Antiviral Activity Study of ABT-538
When Administered Orally as Maintenance Therapy to HIV-Infected Patients
Protocol # M94-247 A phase II safety and efficacy trial of ABT-538 plus current
therapy vs placebo plus current therapy in HIV infected patients.
Protocol # M94-245 A comparative trial of ABT-538 alone, zidovudine alone, or the combination of ABT-538 and zidoudine in HIV-infected patients.
Agouron Pharmaceuticals
Protocol # AG-1343-505 A phase II randomized, double-blind, placebo controlled,
dose range-finding study of Viracept as monotherapy in HIV positive patients.
Protocol # AG-1343-511 A phase II, randomized, double-blind, placebo controlled,
study of Viracept in combination with Zidovudine and Lamivudine vs Zidovudine and
Lamivudine alone in HIV positive patients with little or no prior antiretroviral treatment
Alza Pharmaceuticals
Protocol C95-012 A placebo-controlled evaluation on the effect of chronic
testosterone replacement therapy (Testoderm Testosterone Transdermal
System) on body cell mass and body weight in hypogonadal males with AIDS.
Personally involved with nutritional counseling, body composition analysis, and dietary analysis.
Amgen
Protocol #: GCSF-930101--A Randomized, Controlled, Multicenter Trial of Filgrastim
(Recombinant-methionyl Human Granulocyte Colony Stimulating Factor) for the
Prevention of Grade 4 Neutropenia in Patients with HIV Infection
Bristol-Myers Squibb
Protocol #: 454-999-01--A Treatment IND (Investigational New Drug) Protocol For
The Use of Videx (2', 3'-Dideoxyinosine, ddI) In Patients With Axquired
Immunodeficiency Syndrome (AIDS) Or AIDS Related Complex (ARC) Who Are
Intolerant To Zidovudine (Retrovir)
Protocol # 454-999-02--An Open-Label Study Regimen of Videx (2', 3'-Dideoxyinosine,
ddI) In Patients With Acquired Immunodeficiency Syndrome (AIDS) Exhibiting
Significant Deterioration While Taking Zidovudine (Retrovir)
Protocol # AI455-019--A Double Blind Comparison of Zidovudine (ZDV) Versus
Stavudine (d4T) (BMY 27857) for the Treatment of HIV-Infected Patients with Absolute
CD4+ Lymphocyte Counts Between 50 and 500 cells/mm3 Following at Least 6 Months
of Zidovudine Therapy.
Protocol # AI455-900--A Randomized Blinded Evaluation of Two Doses of d4T
(Stavudine) to Make Treatment Available to Severely Immunocompromised Patients with
HIV Infection Who Have Failed or Are Intolerant of Alternative Antiretroviral Therapy.
Hoechst Roussel Pharmaceuticals
Protocol # 455A A Multicenter, Non-Comparative Trial of the Efficacy of Outpatient
Parenteral Cefotaxime Sodium (Claforan) in the Treatment of HIV Positive Patients with
Infections Caused by Susceptible Pathogens
Intercompany Coolaboration for AIDS Drug Development
Protocol ICC 001 A master protocol to evaluate the safety and efficacy of multidrug
combination antiretroviral therapy for the treatment of HIV infection.
Protocol ICC 002 A master protocol to evaluate the safety and efficacy of multidrug
combination antiretroviral therapy for the treatment of HIV infection
Janssen Research Foundation
Protocol #: ITR-USA-105--A Third-Party Blinded, Randomized Pilot Study of the
Effect of Sporanox Capsules for the Treatment of Oropharyngeal Candidiasis in HIV-
Positive Subjects
Serono Labs
Protocol #: 5341--A Randomized, Parallel Group, Double-Blind, Placebo Controlled
Multicenter Study of Recombinant Growth Hormone (Saizen) in the Treatment of HIV
Associated Catabolism/Wasting
Protocol # 5511--Therapy With Recombinant Human Growth Hormone (Saizen) For
HIV Associated Weight Loss as Continuation Treatment After Serono Study 5341
Protocol # 7033--A Randomized, Parallel Group, Double-blind, Placebo-controlled
Multicenter Study With Mammalian Cell-derived Recombinant Human Growth Hormone
(mhGH) in Adults With AIDS-Associated Catabolism/Weight Loss
Protocol # 7305--Therapy With Mammalian Cell-derived Recombinant Human Growth
Hormone (mhGH) for AIDS-associated Catabolism/Weight Loss
Shaman Pharmaceuticals
Protocol #: SP303T-A-01--A Pilot Study to Determine the Safety and Efficacy of
Topically Applied SP-303T in Patients with Acquired Immunodeficiency Syndrome and
Concomitant Herpes Simplex Virus (HSV) Infection Unresponsive to Acyclovir
Syntex Development Research
Protocol #: GANS2224--An Open-Label Safety Study of Oral Ganciclovir Maintenance
Treatment of CMV Retinitis in People with Limited Venous Access